Drug Database
US

ustekinumab (Qoyvolma)

✓ Approved

Celltrion, Inc. · IL12B · Monoclonal Antibodies

What is ustekinumab?

ustekinumab is a monoclonal antibodies developed by Celltrion, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesQoyvolma
CompanyCelltrion, Inc.
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetIL12B, IL23A
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Celltrion, Inc.

Mechanism of Action

Molecular Targets

ustekinumab acts on 2 molecular targets:

IL12Binterleukin 12B (CLMF2, CLMF)
IL23Ainterleukin 23 subunit alpha (P19, SGRF)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

ustekinumab is developed for 4 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersPsoriatic arthropathy✓ Approved

Related Research Articles

PubMedCancers2026-10-16

Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis.

Matichecchia Cosimo Simone CS, Fanizzi Fabrizio F, Zilli Alessandra A, Ferrara Roberto R et al.

Immune checkpoint inhibitors (ICIs), including anti-CTLA-4, anti-PD-1, and anti-PD-L1 agents, have revolutionized cancer therapy by enhancing T-cell-mediated antitumor responses and significantly improving survival across multiple malignancies. Despite these advances, ICIs are associated with immune-related adverse events (irAEs), with ICI-induced colitis representing one of the most common and severe gastrointestinal toxicities. Clinically and histopathologically, this condition often resembles inflammatory bowel disease (IBD) and can substantially impact treatment continuity and patient quality of life. Corticosteroids remain the standard first-line therapy; however, up to one-third of patients exhibit steroid-refractory disease or develop significant steroid-related toxicity, highlighting the need for alternative therapeutic strategies. Biologic agents, particularly infliximab and vedolizumab, have demonstrated high efficacy in this setting, with infliximab associated with more rapid symptom control and vedolizumab offering a favorable steroid-sparing profile. In patients with multi-refractory disease, additional agents such as ustekinumab, tofacitinib, and tocilizumab have shown promise, although current evidence is limited and primarily derived from small studies and case series. This review critically examines current treatment paradigms for ICI-induced colitis, focusing on efficacy, safety, and potential implications for oncologic outcomes. Despite increasing use of advanced therapies, clinical decision-making remains largely guided by retrospective data, and key uncertainties persist regarding optimal treatment sequencing, patient selection, and long-term safety. Future research should prioritize prospective randomized trials incorporating both oncologic and gastrointestinal endpoints, as well as mechanistic studies aimed at identifying predictive biomarkers and therapeutic targets that preserve anti-tumor immunity.

PMID 42882803
Read full article →
PubMedPolymers2026-10-16

In-Situ Catalytic Pyrolysis of Polystyrene with Sewage Sludge-Derived Catalysts: Sewage Sludge Ash, Sewage Sludge Char, and Fe-Impregnated Acid-Leached Sewage Sludge Char.

Pogorov Fedor F, Tokmurzin Diyar D, Vitoshnova Yelena Y, Zabara Nazar N et al.

Sewage sludge (SS)-derived materials were investigated as low-cost heterogeneous catalytic materials for polystyrene (PS) pyrolysis, focusing on the effects of thermal treatment, HCl leaching, and Fe impregnation. Sewage sludge ash (SSA), sewage sludge char (SSC), and HCl-leached Fe-impregnated sewage sludge char (Fe-LSSC) were evaluated as in-situ catalytic materials. Catalyst-to-PS ratios of 1:1-1:10 were investigated in a horizontal semi-batch tubular reactor operated in an in-situ catalyst-polymer contact mode at 800 °C. Thermal pyrolysis produced 63.9 wt.% PyOil and 12.6 wt.% PyGas. SSA increased the PyOil yield to 78.0 wt.% at 1:10 and promoted lighter aromatics; at 1:1, light aromatics increased to 66.8 wt.%, BTEX from 5.8 to 24.58 wt.%, and PAHs decreased to 11.8 wt.%. SSC showed a weaker, non-monotonic effect, with PyOil decreasing to 54.4 wt.% and PyChar increasing to 4.7 wt.% at 1:2. Fe-LSSC produced the strongest changes, increasing PyGas to 28.0 wt.% at 1:1 and H2 to 75.3 vol.% at 1:2. The gasoline-range fraction reached 82.1 wt.% at 1:2, while PAHs decreased to 8.79 wt.% at 1:1. Catalyst reuse altered gas composition, whereas thermal regeneration partially restored catalytic behavior. Overall, SS-derived materials exhibited distinct, loading-dependent catalytic functions, while HCl leaching and Fe impregnation enhanced the conversion of PS pyrolysis vapors toward lighter aromatic and gaseous products.

PMID 42885004
Read full article →
PubMedPlants (Basel, Switzerland)2026-10-16

Identification of Microalgae, Evaluation of Water Purification Efficiency, and Optimization of Large-Scale Production Conditions Based on Recirculating Aquaculture Systems.

Ou Zekui Z, Yang Gan G, Luo Jiancha J, Huang Dan D et al.

Water purification is the most crucial process for recirculating aquaculture systems (RASs), while microalgae exhibit significant potential for nutrient removal from aquaculture wastewater. Four microalgal species with removal capacities for ammonia nitrogen (NH4+-N), nitrite nitrogen (NO2-N) and total phosphorus (TP) were isolated and identified from the land-based RASs, namely, Kirchneriella cornuta HY-1, Desmodesmus abundans HY-1, Coccomyxa sp. HY-1 and Oocystis sp. HY-1. The growth kinetics were characterized through measurements of cell density, chlorophyll content, and dry biomass in the in situ wastewater. Based on zeta potential, the flocculation efficiencies of seven agents were evaluated. Preservation parameters were optimized under nutrient-supplemented conditions with protective agents. Under large-scale culture conditions, over a 7-day period, the highest NH4+-N removal efficiency of 87.20 ± 0.56% was achieved by C. sp. HY-1, the highest NO2-N removal efficiency (85.63 ± 2.56%) was obtained by O. sp. HY-1, and the maximum TP removal efficiency (71.19 ± 3.35%) was exhibited by K. cornuta HY-1. Moreover, the harvest period could be reached after about 14 days of cultivation. FeCl3 was identified as the optimal harvesting flocculant for all four species. Optimal preservation conditions were determined as 25 °C and 31.25 μmol·m-2·s-1 for D. abundans HY-1, C. sp. HY-1, and O. sp. HY-1, and 25 °C and 18.75 μmol·m-2·s-1 for K. cornuta HY-1. This work provides theoretical guidance for large-scale microalgal production and confirms the technical feasibility of microalgae-driven in situ wastewater remediation.

PMID 42884815
Read full article →
PubMedBritish journal of haematology2026-10-16

Flow cytometric assessment of T-cell receptor β-chain constant region 1/2 skewing as a surrogate marker for clonality in human T-cell leukaemia virus type-1-infected cells.

Jimbo Koji K, Rowan Aileen G AG, Usui Momoko M, Suzuki Kako K et al.

Estimating T-cell clonality within human T-cell leukaemia virus type 1 (HTLV-1)-infected cell populations may aid risk assessment and diagnosis of adult T-cell leukaemia/lymphoma (ATL). However, direct assessment of HTLV-1 integration-site clonality requires genetic analyses that are costly and labour-intensive. We developed a simple flow cytometric surrogate assay by combining the HTLV-1 analysis system by flow cytometry (HAS-Flow) method, which efficiently identifies HTLV-1-infected cells, with T-cell receptor β-chain constant region (TRBC1/2) staining. We analysed 53 HTLV-1-infected individuals, including asymptomatic carriers (n = 25), patients with HTLV-1-associated myelopathy (n = 4) and patients with ATL (n = 24). TRBC1/2 skewing was quantified using the dominant TRBC ratio. The dominant TRBC ratio was significantly higher in ATL than in non-ATL cases and effectively discriminated ATL from non-ATL cases (Area under the receiver operating characteristic curve [AUC], 0.913; 95% confidence interval, 0.803-1.000; p < 0.0001). It correlated with established markers of disease progression, including abnormal lymphocyte burden, proviral load and soluble interleukin-2 receptor levels, as well as clonality assessed by two independent HTLV-1 integration-site-based methods (viral integration site and RAISING-CLOVA). These findings indicate that assessment of TRBC1/2 skewing in HTLV-1-infected cells (HAS-TRBC method) is a simple, cost-effective surrogate for estimating T-cell clonality within HTLV-1-infected cell populations, with potential clinical utility.

PMID 42885517
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

From Food Structure to L-Cell Exposure: How Processing and Digestion Shape Endogenous GLP-1 Responses.

Šantić Roko R, Kumrić Marko M, Tičinović Kurir Tina T, Rušić Doris D et al.

Interest in using foods to stimulate endogenous glucagon-like peptide-1 (GLP-1) has outpaced evidence that transient postprandial increases translate into meaningful physiological outcomes. This review critically examines how food processing and matrix architecture interact with digestion and microbial metabolism to determine the identity, timing, intestinal location, and epithelial accessibility of GLP-1-stimulating ligands. PubMed/MEDLINE, Web of Science Core Collection, BIOSIS Citation Index, and Scopus were searched for the relevant literature. Evidence from cellular systems, organoids, perfused intestines, animal models, and human studies indicates that sugars, amino acids, peptides, fatty acids, monoacylglycerols, bile acids, and microbial metabolites engage distinct nutrient-sensing pathways. However, GLP-1 responses depend not only on chemical composition but also on cellular integrity, particle size, viscosity, starch organization, emulsion structure, protein processing, fermentation, gastric emptying, and the site of intestinal release. These factors can modify the magnitude and kinetics of GLP-1 exposure, although effects vary considerably with material, dose, comparator, population, and experimental model. Whey-containing preloads provide the most consistent acute human evidence, whereas findings for fibres, emulsions, phytochemicals, fermented foods, and controlled-release approaches remain heterogeneous. Importantly, increases in circulating GLP-1 do not consistently coincide with reduced appetite or energy intake, improved glycaemia, or sustained changes in body weight. Food-induced GLP-1 secretion, reduced degradation through dipeptidyl peptidase-4 inhibition, and direct GLP-1 receptor agonism therefore represent distinct biological mechanisms. Overall, food structure can modestly and context-dependently modulate endogenous GLP-1 exposure, but current evidence does not support physiological or therapeutic equivalence with pharmacological GLP-1 receptor agonists.

PMID 42883143
Read full article →
PubMedCancers2026-10-16

Real-World Application of PD-1 Inhibitors in High-Grade Glioma: A Case Series.

Ren Yin Y, Guo Xiaopeng X, Xing Hao H, Kang Xiaoman X et al.

Background/Objectives: Patients with high-grade glioma (HGG) have a poor prognosis despite maximal safe resection, radiotherapy, and chemotherapy, partly because of the immunosuppressive tumor microenvironment. Unfortunately, all phase III trials of anti-PD-1 therapy to date have failed to yield positive results in HGGs. Recent early-phase trials have identified promising strategies involving immune checkpoint inhibitors. Here, we share our 8-year experience with anti-PD-1 therapy in patients with HGG in a real-world setting. Methods: All patients with HGG who received PD-1 inhibitor-based therapy at our center between 2018 and 2026 were included. Medical records were reviewed longitudinally for each patient, and the latest follow-up data were collected. Patients lost to follow-up were excluded. Results: Four regimens involving anti-PD-1 treatment were identified in 22 patients with HGG (newly diagnosed = 11, recurrent = 11): (1) VEGFR-targeted therapy plus PD-1 inhibition (9 recurrent HGGs), (2) the "2-THE-TOP" regimen (tumor-treating fields plus temozolomide and PD-1 inhibitor therapy) (5 newly diagnosed HGGs), (3) anti-PD-1 monotherapy (2 recurrent and 2 newly diagnosed HGGs), and (4) neoadjuvant plus adjuvant anti-PD-1 therapy (4 newly diagnosed HGGs). Median overall survival for these four regimens was 32.7, 20.3, 28.6, and 31.8 months, respectively. No grade 3-4 treatment-related adverse events were recorded. Conclusions: Our preliminary observations suggest that PD-1 blockade may remain a viable option for patients with HGG when combined with specific therapies, administered with careful timing, and applied in selected patients.

PMID 42882817
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ustekinumab